Home » Publications » Other publications of the members

Other publications of the members of IMMUTRAIN

LOGO-IMMUTRAIN-JPEG

Adema GJ, 2019

Moons SJ, Adema GJ, Derks MTGM, Boltje TJ, Büll C.
Sialic acid glycoengineering using N-acetylmannosamine and sialic acid analogues. 
Glycobiology 2019 Mar 26.
JIF 3.7

van den Bijgaart RJE, Kroesen M, Wassink M, Brok IC, Kers-Rebel ED, Boon L, Heise T, van Scherpenzeel M, Lefeber DJ, Boltje TJ, den Brok MH, Hoogerbrugge PM, Büll C, Adema GJ.
Combined sialic acid and HDAC inhibitor treatment upregulates the neuroblastoma antigen GD2.
J Biol Chem 2019 Jan 22
JIF 2.7

Cassetta L, Baekkevold ES, Brandau S, Bujko A, Cassatella MA, Dorhoi A, Krieg C, Lin A, Loré K, Marini O, Pollard JW, Roussel M, Scapini P, Umansky V, Adema GJ.
Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates.
Cancer Immunol Immunother 2019 Jan 25
JIF 4.8

Rabold K, Gielen PR, Kers-Rebel ED, Netea MG, Smit JWA, Adema GJ, Netea-Maier RT.
T-Cell Lymphopenia in Patients with Advanced Thyroid Carcinoma Is Associated with Poor Prognosis.
Oncologist 2019 Jan 3
JIF 5.3

Adema GJ, 2018

Ho NI, Huis In 't Veld LGM, Raaijmakers TK, Adema GJ.
Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?
Front Immunol 2018 Dec 13; 9:2874
JIF 5.5

Heise T, Pijnenborg J, Büll C, van Hilten N, Kers-Rebel E, Balneger N, Elferink H, Adema GJ, Boltje TJ.
Potent metabolic sialylation inhibitors based on C-5 modified fluorinated sialic acids.
J Med Chem 2018 Dec 13
JIF 6.3

Kullaya V, de Jonge MI, Langereis JD, van der Gaast-de Jongh CE, Büll C, Adema GJ, Lefeber D, Cremers AJ, Mmbaga BT, de Groot PG, de Mast Q, van der Ven AJ.
Desialylation of platelets by pneumococcal neuraminidase A induces ADP-dependent platelet hyper-reactivity.
Infect Immun 2018 Jul 23
JIF 3.9

Umansky V, Adema GJ, Baran J, Brandau S, Van Ginderachter JA, Hu X, Jablonska J, Mojsilovic S, Papadaki HA, Pico de Coaña Y, Santegoets KCM, Santibanez JF, Serre K, Si Y, Sieminska I, Velegraki M, Fridlender ZG.
Interactions among myeloid regulatory cells in cancer.
Cancer Immunol Immunother 2018 Jul 12
JIF 4.2

Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, den Brok MH, Adema GJ.
Sialic acid blockade suppresses tumor growth by enhancing T-cell-mediated tumor immunity.
Cancer Res 2018 Jul 1
JIF 9.1

Søndergaard JN, van Heeringen SJ, Looman MWG, Tang C, Triantis V, Louche P, Janssen-Megens EM, Sieuwerts AM, Martens JWM, Logie C, Stunnenberg HG, Ansems M, Adema GJ.
Dendritic cells actively limit interleukin-10 production under inflammatory conditions via DC-SCRIPT and dual-specificity phosphatase 4.
Front Immunol 2018 Jun 22
JIF 5.5

Heise T, Langereis JD, Rossing E, de Jonge MI, Adema GJ, Büll C, Boltje TJ.
Selective inhibition of sialic acid-based molecular mimicry in haemophilus influenzae abrogates serum resistance.
Cell Chem Biol 2018 Jun 9
JIF 5.6

den Brok MH, Raaijmakers TK, Collado-Camps E, Adema GJ.
Lipid droplets as immune modulators in myeloid cells.
Trends Immunol 2018 May
JIF 10.5

Bourquin C, 2019

Bourquin C, Pommier A, Hotz C.
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists.
Pharmacol Res. 2019 Mar 2.
JIF 4.4

Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
J Exp Med. 2019 Mar 25.
JIF 10.8

Bourquin C.
Bionanomaterials for the Delivery of Cancer Immunotherapy.
Chimia (Aarau). 2019 Feb 27;73(1):69-72.
JIF 1.2

Bourquin C, 2018

Spöring I, Martinez VA, Hotz C, Schwarz-Linek J, Grady KL, Nava-Sedeño JM, Vissers T, Singer HM, Rohde M, Bourquin C, Hatzikirou H, Poon WCK, Dufour YS, Erhardt M.
Hook length of the bacterial flagellum is optimized for maximal stability of the flagellar bundle.
PLoS Biol 2018 Sep 6
JIF 9.1

Lucke M, Mottas I, Herbst T, Hotz C, Römer L, Schierling M, Herold HM, Slotta U, Spinetti T, Scheibel T, Winter G, Bourquin C*, Engert J*.
Engineered hybrid spider silk particles as delivery system for peptide vaccines.
Biomaterials. 2018 Jul
JIF 8.4

Widmer J, Thauvin C, Mottas I, Nguyen VN, Delie F, Allémann E, Bourquin C.
Polymer-based nanoparticles loaded with a TLR7 ligand to target the lymph node for immunostimulation.
Int J Pharm 2018 Jan 15
JIF 0.3

Endres S, Kobold S, Koenig LM, Schnurr M, 2019

Rapp M, Wintergerst MWM, Kunz WG, Vetter VK, Knott MML, Lisowski D, Haubner S, Moder S, Thaler R, Eiber S, Meyer B, Röhrle N, Piseddu I, Grassmann S, Layritz P, Kühnemuth B, Stutte S, Bourquin C, von Andrian UH, Endres S, Anz D.
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes.
J Exp Med. 2019 Mar 25.
JIF 10.8

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
BMC Cancer. 2018 Dec 20;18(1):1278.
JIF 3.3

Darowski D, Kobold S, Jost C, Klein C.
Combining the best of two worlds: Highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
MAbs. 2019 Mar 20.
JIF 5.2

Düwell P, Heidegger S, Kobold S.
Innate Immune Stimulation in Cancer Therapy. 
Hematol Oncol Clin North Am. 2019 Apr;33(2):215-231.
JIF 3.1

Libby P, Kobold S.
Inflammation: A Common Contributor to Cancer, Aging, and Cardiovascular Diseases.
Cardiovasc Res. 2019 Mar 4.
JIF 6.3

Kobold S.
Innate and adaptive immunity combined for cancer treatment.
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1087-1088.
JIF 9.5

Zhang J, Endres S, Kobold S.
Enhancing tumor T cell infiltration to enable cancer immunotherapy
Immunotherapy 2019 Feb;11(3):201-213.
JIF 3.5

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J.
Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.
Hepatology 2019 Jan
JIF 10.8

Endres S, Kobold S, Koenig LM, Schnurr M, 2018

Kobold S.
Innate and adaptive immunity combined for cancer treatment.
Proc Natl Acad Sci USA 2018 Dec 17
JIF 10.4

Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D.
CCL1 is a major regulatory T cell attracting factor in human breast cancer.
BMC Cancer 2018 Dec 20
JIF 3.3

Wiedemann GM, Aithal C, Kraechan A, Heise C, Cadilha BL, Zhang J, Duewell P, Ballotti R, Endres S, Bertolotto C, Kobold S.
Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma.
Transl Oncol 2018 Nov 28
JIF 3.1

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018 Oct 1
JIF 15.1

Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiol Rep 2018 Aug
JIF 1.6

Kobold S, Pantelyushin S, Rataj F, vom Berg J.
Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy.
Frontiers in Oncology 2018 Jul
JIF 4.7

Kobold S, Krackhardt A, Schlösser H, Wolf D.
[Immuno-oncology: A brief overview].
Dtsch Med Wochenschr 2018 Jul
JIF 0.1

Metzger P, Kirchleitner SV, Koenig LM, Hörth C, Kobold S, Endres S, Schnurr M, Duewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Sci Rep 2018 Jun 11
JIF 4.8

Gottschlich A, Endres S, Kobold S.
Can we use interleukin-1β blockade for lung cancer treatment?
Transl Lung Cancer Res 2018 Apr;7(Suppl 2):S160-S164.
JIF 1.8

Markota A, Endres S, Kobold S.
Targeting interleukin-22 for cancer therapy.
Hum Vaccin Immunother 2018 Apr 4
JIF 2.2

Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Science 2018 Mar 30
JIF 35.3

Mak'Anyengo R, Duewell P, Reichl C, Hörth C, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold S, Endres S, Schnurr M, Bauer C.
Nlrp3-dependent IL-1β inhibits CD103+ dendritic cell differentiation in the gut.
JCI Insight 2018 Mar 8

Damby DE, Horwell CJ, Baxter PJ, Kueppers U, Schnurr M, Dingwell DB, Duewell P.
Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Front Immunol 2018 Jan 22
JIF 4.2

Hopfner KP, 2018

Dialer CR, Stazzoni S, Drexler DJ, Müller FM, Veth S, Pichler A, Okamura H, Witte G, Hopfner KP, Carell T.
A Click-Chemistry Linked 2'3'-cGAMP Analog.
Chemistry 2018 Dec 10
JIF 5.2

Butryn A, Woike S, Shetty SJ, Auble DT, Hopfner KP.
Crystal structure of the full Swi2/Snf2 remodeler Mot1 in the resting state.
Elife 2018 Oct 5
JIF 7.7

Schlauderer F, Seeholzer T, Desfosses A, Gehring T, Strauss M, Hopfner KP, Gutsche I, Krappmann D, Lammens K.
Molecular architecture and regulation of BCL10-MALT1 filaments.
Nat Commun 2018 Oct 2
JIF 12.4

Saathoff JH, Käshammer L, Lammens K, Byrne RT, Hopfner KP.
The bacterial Mre11-Rad50 homolog SbcCD cleaves opposing strands of DNA by two chemically distinct nuclease reactions.
Nucleic Acids Res 2018 Oct 2
JIF 11.6

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018 Oct 1
JIF 15.1

Knoll KR, Eustermann S, Niebauer V, Oberbeckmann E, Stoehr G, Schall K, Tosi A, Schwarz M, Buchfellner A, Korber P, Hopfner KP.
The nuclear actin-containing Arp8 module is a linker DNA sensor driving INO80 chromatin remodeling.
Nat Struct Mol Biol 2018 Sep
JIF 13.3

Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Oncoimmunology 2018 Jul 30
JIF 5.5

Lässig C, Lammens K, Gorenflos López JL, Michalski S, Fettscher O, Hopfner KP.
Unified mechanisms for self-RNA recognition by RIG-I Singleton-Merten syndrome variants.
Elife 2018 Jul 26
JIF 7.7

Eustermann S, Schall K, Kostrewa D, Lakomek K, Strauss M, Moldt M, Hopfner KP.
Structural basis for ATP-dependent chromatin remodelling by the INO80 complex.
Nature 2018 Apr
JIF 44.9

Kotlarz D, Marquardt B, Barøy T, Lee WS, Konnikova L, Hollizeck S, Magg T, Lehle AS, Walz C, Borggraefe I, Hauck F, Bufler P, Conca R, Wall SM, Schumacher EM, Misceo D, Frengen E, Bentsen BS, Uhlig HH, Hopfner KP, Muise AM, Snapper SB, Strømme P, Klein C.
Human TGF-β1 deficiency causes severe inflammatory bowel disease and encephalopathy.
Nat Genet 2018 Mar
JIF 31.2

Schwarz M, Schall K, Kallis E, Eustermann S, Guariento M, Moldt M, Hopfner KP, Michaelis J.
Single-molecule nucleosome remodeling by INO80 and effects of histone tails.
FEBS Lett 2018 Feb
JIF 4.5

Chiang JJ, Sparrer KMJ, van Gent M, Lässig C, Huang T, Osterrieder N, Hopfner KP, Gack MU.
Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity.
Nat Immunol 2018 Jan
JIF 21.9

Jäck HM, 2018

Urbanczyk S, Stein M, Schuh W, Jäck HM, Mougiakakos D, Mielenz D.
Regulation of Energy Metabolism during Early B Lymphocyte Development.
Int J Mol Sci 2018 Jul 27
JIF 3.9

Haberland K, Ackermann JA, Ipseiz N, Culemann S, Pracht K, Englbrecht M, Jäck HM, Schett G, Schuh W, Krönke G.
Eosinophils are not essential for maintenance of murine plasma cells in the bone marrow.
Eur J Immunol 2018 May
JIF 4.2

Dreyer FS, Cantone M, Eberhardt M, Jaitly T, Walter L, Wittmann J, Gupta SK, Khan FM, Wolkenhauer O, Pützer BM, Jäck HM, Heinzerling L, Vera J.
A web platform for the network analysis of high-throughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy.
Biochim Biophys Acta 2018 Jun
JIF 5.2

Meinzinger J, Jäck HM, Pracht K.
miRNA meets plasma cells "How tiny RNAs control antibody responses".
Clin Immunol 2018 Jan;186:3-8
JIF 3.6

Klein C, 2018

Ribba B, Boetsch C, Nayak T, Grimm HP, Charo J, Evers S, Klein C, Tessier J, Charoin JE, Phipps A, Pisa P, Teichgräber V.
Prediction of the optimal dosing regimen using a mathematical model of tumor uptake for immunocytokine-based cancer immunotherapy.
Clin Cancer Res 2018 Jul 15
JIF 10.2

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A.
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.
Nat Med 2018 Jun 11
JIF 33.4

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter WF, Bray-French K, Hinton HJ, Giusti AMF, Freimoser-Grundschober A, Larivière L, Neumann C, Klein C, Umana P.
CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies.
Clin Cancer Res 2018 May 1
JIF 10.2

Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S.
The PI3Kδ-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in vivo.
J Immunol 2018 Apr 1
JIF 5.2

Hassenrück F, Knödgen E, Göckeritz E, Midda SH, Vondey V, Neumann L, Herter S, Klein C, Hallek M, Krause G.
Sensitive detection of the natural killer cell-mediated cytotoxicity of anti-CD20 antibodies and its impairment by B-cell receptor pathway inhibitors.
Biomed Res Int 2018 Mar 19
JIF 2.6

Meyer S, Evers M, Jansen JHM, Buijs J, Broek B, Reitsma SE, Moerer P, Amini M, Kretschmer A, Ten Broeke T, den Hartog MT, Rijke M, Klein C, Valerius T, Boross P, Leusen JHW.
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies.
Br J Haematol 2018 Mar
JIF 5.7

Hartimath SV, Manuelli V, Zijlma R, Signore A, Nayak TK, Freimoser-Grundschober A, Klein C, Dierckx RAJO, de Vries EFJ.
Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.
Oncotarget 2018 Jan 2
JIF 5.2

Regad T, 2018

La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, Papaccio F, Desiderio V, Tirino V.
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
J Exp Clin Cancer Res 2018 Dec 3
JIF 6.2

Mele L, Paino F, Papaccio F, Regad T, Boocock D, Stiuso P, Lombardi A, Liccardo D, Aquino G, Barbieri A, Arra C, Coveney C, La Noce M, Papaccio G, Caraglia M, Tirino V, Desiderio V.
A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo.
Cell Death Dis 2018 May 1
JIF 4.6

Vadakekolathu J, Al-Juboori SIK, Johnson C, Schneider A, Buczek ME, Di Biase A, Pockley AG, Ball GR, Powe DG, Regad T.
MTSS1 and SCAMP1 cooperate to prevent invasion in breast cancer.
Cell Death Dis 2018 Mar 1
JIF 4.6

Balahmar RM, Boocock DJ, Coveney C, Ray S, Vadakekolathu J, Regad T, Ali S, Sivasubramaniam S.
Identification and characterisation of NANOG+/ OCT-4high/SOX2+ doxorubicin-resistant stem-like cells from transformed trophoblastic cell lines.
Oncotarget 2018 Jan 11
JIF 5.2

Rescigno M, 2019

Guglietta S, Rescigno M.
Gone with the Antibody. 
Immunity 2018 Sep 18;49(3):386-388.
JIF 19.7

Caprara G, Prosperini E, Piccolo V, Sigismondo G, Melacarne A, Cuomo A, Boothby M, Rescigno M, Bonaldi T, Natoli G.
PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins.
J Immunol. 2018 Apr 1;200(7):2439-2454.
JIF 5.2

Burrello C, Pellegrino G, Giuffrè MR, Lovati G, Magagna I, Bertocchi A, Cribiù FM, Boggio F, Botti F, Trombetta E, Porretti L, Di Sabatino A, Vecchi M, Rescigno M, Caprioli F, Facciotti F.
Mucosa-associated microbiota drives pathogenic functions in IBD-derived intestinal iNKT cells. 
Life Sci Alliance. 2019 Feb 13;2(1).

Rescigno M, 2018

Burrello C, Garavaglia F, Cribiù FM, Ercoli G, Lopez G, Troisi J, Colucci A, Guglietta S, Carloni S, Guglielmetti S, Taverniti V, Nizzoli G, Bosari S, Caprioli F, Rescigno M, Facciotti F.
Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells.
Nat Commun 2018 Dec 5
JIF 12.4

Nizzoli G, Burrello C, Cribiù FM, Lovati G, Ercoli G, Botti F, Trombetta E, Porretti L, Todoerti K, Neri A, Giuffrè MR, Geginat J, Vecchi M, Rescigno M, Paroni M, Caprioli F, Facciotti F.
Pathogenicity of In Vivo Generated Intestinal Th17 Lymphocytes is IFNγ Dependent.
J Crohns Colitis 2018 Jul 30
JIF 6.6

Guglietta S, Rescigno M.
Gone with the Antibody.
Immunity 2018 Sep 18
JIF 22.8

Nizzoli G, Burrello C, Cribiù FM, Lovati G, Ercoli G, Botti F, Trombetta E, Porretti L, Todoerti K, Neri A, Giuffrè MR, Geginat J, Vecchi M, Rescigno M, Paroni M, Caprioli F, Facciotti F.
Pathogenicity of in-vivo generated intestinal Th17 lymphocytes is IFNγ dependent.
J Crohns Colitis 2018 Apr 25.
JIF 5.8

Mosca F, Gianni ML, Rescigno M.
Can Postbiotics Represent a New Strategy for NEC?
Adv Exp Med Biol 2019 Jan 18
JIF 1.8

Soengas MS, 2019

Bagati A, Moparthy S, Fink EE, Bianchi-Smiraglia A, Yun DH, Kolesnikova M, Udartseva OO, Wolff DW, Roll MV, Lipchick BC, Han Z, Kozlova NI, Jowdy P, Berman AE, Box NF, Rodriguez C, Bshara W, Kandel ES, Soengas MS, Paragh G, Nikiforov MA.
KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
Oncogene 2019 Jan 21
JIF 6.9

Soengas MS, 2018

Karras P, Riveiro-Falkenbach E, Cañón E, Tejedo C, Calvo TG, Martínez-Herranz R, Alonso-Curbelo D, Cifdaloz M, Perez-Guijarro E, Gómez-López G, Ximenez-Embun P, Muñoz J, Megias D, Olmeda D, Moscat J, Ortiz-Romero PL, Rodríguez-Peralto JL, Soengas MS.
p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors.
Cancer Cell 2018 Dec 1
JIF 22.8

Pérez-Guijarro E, Karras P, Cifdaloz M, Martínez-Herranz R, Cañón E, Graña O, Horcajada-Reales C, Alonso-Curbelo D, Calvo TG, Gómez-López G, Bellora N, Riveiro-Falkenbach E, Ortiz-Romero PL, Rodríguez-Peralto JL, Maestre L, Roncador G, de Agustín Asensio JC, Goding CR, Eyras E, Megías D, Méndez R, Soengas MS.
Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers.
Nat Commun 2016 Nov 18
JIF 12.1

Martinez-Useros J, Moreno I, Fernandez-Aceñero MJ, Rodriguez-Remirez M, Borrero-Palacios A, Cebrian A, Gomez Del Pulgar T, Del Puerto-Nevado L, Li W, Puime-Otin A, Perez N, Soengas MS, Garcia-Foncillas J.
The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
BMC Cancer 2018 Feb 6
JIF 3.3

Stoitzner P, 2018

Sparber F, Dolowschiak T, Mertens S, Lauener L, Clausen BE, Joller N, Stoitzner P, Tussiwand R, LeibundGut-Landmann S.
Langerin+ DCs regulate innate IL-17 production in the oral mucosa during Candida albicans-mediated infection.
PLoS Pathog 2018 May 21
JIF 6.6

Straten PT, 2018

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK. J.
Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.
J.Immunol. 2018 Apr
JIF 5.2

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature 2018 Dec 19
JIF 45

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.
Leukemia 2018 Feb
JIF 10

Shraibman B, Barnea E, Melamed Kadosh D, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, Von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.
Identification of tumor antigens among the HLA peptidomes of Glioblastoma tumors and plasma.
Mol Cell Proteomics 2018 Aug 2
JIF 6.5

Idorn M, Thor Straten P.
Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site.
Cells 2018 Aug 17
JIF 4.8

Idorn M, Skadborg SK, Kellermann L, Halldórsdóttir HR, Holmen Olofsson G, Met Ö, Thor Straten P.
Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.
Oncoimmunology 2018 Apr 18
JIF 5.5

Strobl S, 2018

Hahn F, Hutterer C, Henry C, Hamilton ST, Strojan H, Kraut A, Schulte U, Schütz M, Kohrt S, Wangen C, Pfizer J, Couté Y, Rawlinson WD, Strobl S, Marschall M.
Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity.
Antiviral Res 2018 Sep 27.
JIF 4.3

Zinser E, Krawczyk A, Mühl-Zürbes P, Aufderhorst U, Draßner C, Stich L, Zaja M, Strobl S, Steinkasserer A, Heilingloh CS.
A new promising candidate to overcome drug resistant herpes simplex virus infections.
Antiviral Res 2018 Jan
JIF 4.2

Zitvogel, 2019

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.
T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.
Ann Oncol. 2019 Mar 29.
JIF 10.6

Perez-Lanzon M, Zitvogel L, Kroemer G.
Failure of immunosurveillance accelerates aging.
Oncoimmunology. 2019 Feb 9
JIF 5.5

Zitvogel L, 2018

Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G.
Anticancer effects of anti-CD47 immunotherapy in vivo. 
Oncoimmunology. 2018 Dec 11;8(3):1550619.
JIF 5.5

Frazao A, Messaoudene M, Núñez N, Dulphy N, Roussin F, Sedlik C, Zitvogel L, Piaggio E, Toubert A, Caignard A.
CD16+NKG2Ahigh Natural Killer cells infiltrate breast cancer draining lymph nodes
Cancer Immunol Res 2018 Dec 4
JIF 7.2

Jacquelot N, Zitvogel L, Eggermont AM.
Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.
Nat Commun. 2018 Jul 26

Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G.
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals.
Cell Death Dis 2018 Oct 23
JIF 6.2

Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B.
The intimate relationship between gut microbiota and cancer immunotherapy.
Gut Microbes 2018 Oct 19
JIF 4.2

Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
Trial Watch: Toll-like receptor agonists in cancer immunotherapy.
Oncoimmunology 2018 Oct 11
JEF 5.5

Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G.
Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy.
Oncoimmunology 2018 Oct 1
JIF 5.5

Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
Trial watch: Peptide-based vaccines in anticancer therapy.
Oncoimmunology 2018 Sep 6
JIF 5.5

G Pol J, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, R Clements D, Fahrner JE, Fend L, C Bell J, L Mossman K, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Oncoimmunology 2018 Aug 27
JIF 5.5

Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G.
TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.
Oncoimmunology 2018 Aug 1
JIF 5.5

Jacquelot N, Zitvogel L, Eggermont AM.
Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.
Nat Commun 2018 Jul 26
JIF 12.4

Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G.
The gut microbiota influences anticancer immunosurveillance and general health.
Nat Rev Clin Oncol 2018 Jun;15(6):382-396.
JIF 20.6

Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B.
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
Ann Oncol 2018 Jun 1
JIF 13.9

Goubet AG, Daillère R, Routy B, Derosa L, M Roberti P, Zitvogel L.
The impact of the intestinal microbiota in therapeutic responses against cancer.
C R Biol 2018 May - Jun
JIF 1.3

Derosa L, Routy B, Kroemer G, Zitvogel L.
The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1.
Oncoimmunology 2018 Apr 18
JIF 7.7

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, Annicchiarico-Petruzzelli M, Antonov AV, Arama E, Baehrecke EH, Barlev NA, Bazan NG, Bernassola F, Bertrand MJM, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Boya P, Brenner C, Campanella M, Candi E, Carmona-Gutierrez D, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Cohen GM, Conrad M, Cubillos-Ruiz JR, Czabotar PE, D'Angiolella V, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, DeBerardinis RJ, Deshmukh M, Di Daniele N, Di Virgilio F, Dixit VM, Dixon SJ, Duckett CS, Dynlacht BD, El-Deiry WS, Elrod JW, Fimia GM, Fulda S, García-Sáez AJ, Garg AD, Garrido C, Gavathiotis E, Golstein P, Gottlieb E, Green DR, Greene LA, Gronemeyer H, Gross A, Hajnoczky G, Hardwick JM, Harris IS, Hengartner MO, Hetz C, Ichijo H, Jäättelä M, Joseph B, Jost PJ, Juin PP, Kaiser WJ, Karin M, Kaufmann T, Kepp O, Kimchi A, Kitsis RN, Klionsky DJ, Knight RA, Kumar S, Lee SW, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lowe SW, Luedde T, Lugli E, MacFarlane M, Madeo F, Malewicz M, Malorni W, Manic G, Marine JC, Martin SJ, Martinou JC, Medema JP, Mehlen P, Meier P, Melino S, Miao EA, Molkentin JD, Moll UM, Muñoz-Pinedo C, Nagata S, Nuñez G, Oberst A, Oren M, Overholtzer M, Pagano M, Panaretakis T, Pasparakis M, Penninger JM, Pereira DM, Pervaiz S, Peter ME, Piacentini M, Pinton P, Prehn JHM, Puthalakath H, Rabinovich GA, Rehm M, Rizzuto R, Rodrigues CMP, Rubinsztein DC, Rudel T, Ryan KM, Sayan E, Scorrano L, Shao F, Shi Y, Silke J, Simon HU, Sistigu A, Stockwell BR, Strasser A, Szabadkai G, Tait SWG, Tang D, Tavernarakis N, Thorburn A, Tsujimoto Y, Turk B, Vanden Berghe T, Vandenabeele P, Vander Heiden MG, Villunger A, Virgin HW, Vousden KH, Vucic D, Wagner EF, Walczak H, Wallach D, Wang Y, Wells JA, Wood W, Yuan J, Zakeri Z, Zhivotovsky B, Zitvogel L, Melino G, Kroemer G.
Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Cell Death Differ 2018 Mar
JIF 5.7

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF.
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.
Science 2018 Mar 23
JIF 37.2

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.
NKp46 receptor-mediated interferon-γ production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis.
Immunity 2018 Feb 20
JIF 14.7

Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, Degli-Esposti MA, Vivier E, Waddell N, Linden J, Huntington ND, Souza-Fonseca-Guimaraes F, Smyth MJ.
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment.
Cancer Res 2018 Feb 15; 78(4):1003-1016
JIF 9.1

García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.
Trial watch: immunostimulation with recombinant cytokines for cancer therapy.
Oncoimmunology 2018 Feb 15
JIF 7.7

Kroemer G, Zitvogel L.
Cancer immunotherapy in 2017: the breakthrough of the microbiota.
Nat Rev Immunol 2018 Jan 30
JIF 46.5

Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, Senovilla L, Kepp O, Kroemer G.
eIF2α phosphorylation is pathognomonic for immunogenic cell death.
Cell Death Differ 2018 Jan 22
JIF 5.7

Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, Scope A, Neuman T, Enk CD, Hanna JH, Sexl V, Jonjic S, Seliger B, Zitvogel L, Mandelboim O.
NKp46 receptor-mediated interferon-γ production by natural killer cells increases fibronectin 1 to alter tumor architecture and control metastasis.
Immunity 2018 Jan 16
JIF 22.9